CAR-CD19 T cell therapy

CT032人源化抗CD19自体CAR T细胞

Report date: 2024/09/20 09:54:31

Base Information

Drug NameCAR-CD19 T cell therapy
Drug Alias NameCT032人源化抗CD19自体CAR T细胞注射液Anti-CD19 chimeric antigen receptor T cell therapy - CARsgenCD19 Redirected Autologous Cells - CARsgenCT032 CAR-CD19 T cells - CARsgenCAR-CD19 T cells - CARsgen +[6] 
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Donor > Autologous
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, B-CellLymphoma, Non-HodgkinLymphoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesCarsgen Biomedicine (Shanghai) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHK inno.N CorporationCarsgen Biomedicine (Shanghai) Co LtdShanghai Carsgen Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellLymphoma, Non-Hodgkin
Inactive IndicationsLymphomaLeukemia, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A